U.S. Markets closed

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.20-0.75 (-0.78%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close96.86
Open96.71
Bid95.74 x 1400
Ask95.91 x 1000
Day's Range95.66 - 98.29
52 Week Range56.00 - 125.61
Volume209,752
Avg. Volume437,211
Market Cap5.518B
Beta (5Y Monthly)0.73
PE Ratio (TTM)17.03
EPS (TTM)5.59
Earnings DateMay 04, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est117.62
  • Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
    PR Newswire

    Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021

    Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) program are being reported at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The presentations focus on registrational PATHFINDER trial data of AYVAKIT™ (avapritinib) in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders.

  • Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
    PR Newswire

    Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021

    Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precision therapy pipeline at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. Collectively, the presentations, including foundational preclinical data for multiple programs, demonstrate the productivity of the company's scientific platform. Additional presentations of clinical data for AYVAKIT™ (avapritinib) and BLU-263 will be reported on Sunday, April 11, 2021.

  • Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on April 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 27,543 shares of its common stock and an aggregate of 13,792 restricted stock units (RSUs) to 14 new employees under Blueprint Medicines' 2020 Inducement Plan.